Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System
Background: Multiple sclerosis (MS) is a severe and common autoimmune disorder of the central nervous system. Despite the availability of several novel treatment options, the disease is still poorly controlled, since the pathophysiological mechanisms are not fully understood. Methods: We tested the...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cell Physiol Biochem Press GmbH & Co KG
2017-11-01
|
| Series: | Neurosignals |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/484621 |
| _version_ | 1818528715186896896 |
|---|---|
| author | Katrin Anne Becker Ramona Halmer Laura Davies Brian D. Henry Regan Ziobro-Henry Yann Decker Yang Liu Erich Gulbins Klaus Fassbender Silke Walter |
| author_facet | Katrin Anne Becker Ramona Halmer Laura Davies Brian D. Henry Regan Ziobro-Henry Yann Decker Yang Liu Erich Gulbins Klaus Fassbender Silke Walter |
| author_sort | Katrin Anne Becker |
| collection | DOAJ |
| description | Background: Multiple sclerosis (MS) is a severe and common autoimmune disorder of the central nervous system. Despite the availability of several novel treatment options, the disease is still poorly controlled, since the pathophysiological mechanisms are not fully understood. Methods: We tested the role of the acid sphingomyelinase/ceramide system in a model of MS, i.e. experimental autoimmune encephalomyelitis (EAE). Mice were immunized with myelin-oligodendrocyte glycoprotein and the development of the disease was analyzed by histology, immunological tests and clinical assessment in wildtype and acid sphingomyelinase (Asm)-deficient mice. Results: Genetic deficiency of acid sphingomyelinase (Asm) protected against clinical symptoms in EAE and markedly attenuated the characteristic detrimental neuroinflammatory response. T lymphocyte adhesion, integrity of tight junctions, blood-brain barrier disruption and subsequent intracerebral infiltration of inflammatory cells were blocked in Asm-deficient mice after immunization. This resulted in an almost complete block of the development of disease symptoms in these mice, while wildtype mice showed severe neurological symptoms typical for EAE. Conclusion: Activation of the Asm/ceramide system is a central step for the development of EAE. Our findings may serve to identify novel therapeutic strategies for MS patients. |
| first_indexed | 2024-12-11T06:53:36Z |
| format | Article |
| id | doaj.art-af96f4fd834c48758e036fee0112c0e6 |
| institution | Directory Open Access Journal |
| issn | 1424-862X 1424-8638 |
| language | English |
| last_indexed | 2024-12-11T06:53:36Z |
| publishDate | 2017-11-01 |
| publisher | Cell Physiol Biochem Press GmbH & Co KG |
| record_format | Article |
| series | Neurosignals |
| spelling | doaj.art-af96f4fd834c48758e036fee0112c0e62022-12-22T01:16:49ZengCell Physiol Biochem Press GmbH & Co KGNeurosignals1424-862X1424-86382017-11-01251889710.1159/000484621484621Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide SystemKatrin Anne BeckerRamona HalmerLaura DaviesBrian D. HenryRegan Ziobro-HenryYann DeckerYang LiuErich GulbinsKlaus FassbenderSilke WalterBackground: Multiple sclerosis (MS) is a severe and common autoimmune disorder of the central nervous system. Despite the availability of several novel treatment options, the disease is still poorly controlled, since the pathophysiological mechanisms are not fully understood. Methods: We tested the role of the acid sphingomyelinase/ceramide system in a model of MS, i.e. experimental autoimmune encephalomyelitis (EAE). Mice were immunized with myelin-oligodendrocyte glycoprotein and the development of the disease was analyzed by histology, immunological tests and clinical assessment in wildtype and acid sphingomyelinase (Asm)-deficient mice. Results: Genetic deficiency of acid sphingomyelinase (Asm) protected against clinical symptoms in EAE and markedly attenuated the characteristic detrimental neuroinflammatory response. T lymphocyte adhesion, integrity of tight junctions, blood-brain barrier disruption and subsequent intracerebral infiltration of inflammatory cells were blocked in Asm-deficient mice after immunization. This resulted in an almost complete block of the development of disease symptoms in these mice, while wildtype mice showed severe neurological symptoms typical for EAE. Conclusion: Activation of the Asm/ceramide system is a central step for the development of EAE. Our findings may serve to identify novel therapeutic strategies for MS patients.https://www.karger.com/Article/FullText/484621Multiple sclerosisAcid sphingomyelinaseCeramideTight junctionsExperimental autoimmune encephalomyelitis |
| spellingShingle | Katrin Anne Becker Ramona Halmer Laura Davies Brian D. Henry Regan Ziobro-Henry Yann Decker Yang Liu Erich Gulbins Klaus Fassbender Silke Walter Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System Neurosignals Multiple sclerosis Acid sphingomyelinase Ceramide Tight junctions Experimental autoimmune encephalomyelitis |
| title | Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System |
| title_full | Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System |
| title_fullStr | Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System |
| title_full_unstemmed | Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System |
| title_short | Blockade of Experimental Multiple Sclerosis by Inhibition of the Acid Sphingomyelinase/Ceramide System |
| title_sort | blockade of experimental multiple sclerosis by inhibition of the acid sphingomyelinase ceramide system |
| topic | Multiple sclerosis Acid sphingomyelinase Ceramide Tight junctions Experimental autoimmune encephalomyelitis |
| url | https://www.karger.com/Article/FullText/484621 |
| work_keys_str_mv | AT katrinannebecker blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT ramonahalmer blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT lauradavies blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT briandhenry blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT reganziobrohenry blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT yanndecker blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT yangliu blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT erichgulbins blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT klausfassbender blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem AT silkewalter blockadeofexperimentalmultiplesclerosisbyinhibitionoftheacidsphingomyelinaseceramidesystem |